High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer

High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung... Background The status of antitumor immunity represented by the expression of programmed cell death-1 (PD-1)/pro- grammed cell death-ligand 1 (PD-L1) and immune cell (IC) infiltration is unknown in HIV-infected patients with non-small cell lung cancer (NSCLC). Methods Fifteen HIV-infected patients with NSCLC were compared with 29 non-HIV-infected patients with NSCLC. Analysis of 13 propensity-score-matched patients in the two groups was also compared. The expression of PD-1/PD-L1 and + + + tumor infiltration by CD4, CD8 , and CD56 immune cells were examined by immunohistochemistry; score of ≥ 2 was defined as positive. Results Although high PD-L1 expression in tumor cells was observed in HIV and non-HIV cohorts, the association of PD-1/ PD-L1 was significant only in the HIV cohort. In overall as well as the propensity-matched analyses, HIV-infected patients with high PD-L1 expression showed shorter survival than HIV-infected patients with low PD-L1 expression; no significant difference was observed in this respect in the non-HIV cohort. Conclusion High PD-L1 expression in tumor tissue was associated with poor prognosis in HIV-infected NSCLC patients but not in non-HIV-infected NSCLC patients. These results suggest that antitumor immunity by PD-1/PD-L1 axis might be suppressed more in HIV-infected NSCLC patients as compared to their non-HIV-infected http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Immunology, Immunotherapy Springer Journals

High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer

Loading next page...
 
/lp/springer_journal/high-pd-l1-expression-indicates-poor-prognosis-of-hiv-infected-PItB3oAktd
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Immunology; Cancer Research
ISSN
0340-7004
eISSN
1432-0851
D.O.I.
10.1007/s00262-017-2103-y
Publisher site
See Article on Publisher Site

Abstract

Background The status of antitumor immunity represented by the expression of programmed cell death-1 (PD-1)/pro- grammed cell death-ligand 1 (PD-L1) and immune cell (IC) infiltration is unknown in HIV-infected patients with non-small cell lung cancer (NSCLC). Methods Fifteen HIV-infected patients with NSCLC were compared with 29 non-HIV-infected patients with NSCLC. Analysis of 13 propensity-score-matched patients in the two groups was also compared. The expression of PD-1/PD-L1 and + + + tumor infiltration by CD4, CD8 , and CD56 immune cells were examined by immunohistochemistry; score of ≥ 2 was defined as positive. Results Although high PD-L1 expression in tumor cells was observed in HIV and non-HIV cohorts, the association of PD-1/ PD-L1 was significant only in the HIV cohort. In overall as well as the propensity-matched analyses, HIV-infected patients with high PD-L1 expression showed shorter survival than HIV-infected patients with low PD-L1 expression; no significant difference was observed in this respect in the non-HIV cohort. Conclusion High PD-L1 expression in tumor tissue was associated with poor prognosis in HIV-infected NSCLC patients but not in non-HIV-infected NSCLC patients. These results suggest that antitumor immunity by PD-1/PD-L1 axis might be suppressed more in HIV-infected NSCLC patients as compared to their non-HIV-infected

Journal

Cancer Immunology, ImmunotherapySpringer Journals

Published: Dec 14, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off